Why Bio-Path Stock Is Climbing Today
Why Bio-Path Stock Is Climbing Today
Bio-Path Holdings, Inc. (NASDAQ:BPTH) shares are trading higher Friday after the company announced interim results from its Phase 2 study of prexigebersen in combination with decitabine and venetoclax for the treatment of acute myeloid leukemia.
Bio-Path Holdings, Inc.（納斯達克：BPTH）股票週五上漲，因公司宣佈了與去甲鞘氨基葡萄糖和文尼托克拉克聯合治療急性髓性白血病的前烯鳥苷前瞻性 2 相研究的中期結果。
The Details:
細節：
Bio-Path said the data presented showed prexigebersen continues to be well-tolerated and demonstrated efficacy results in two reporting cohorts including evaluable newly diagnosed AML patients and evaluable refractory/relapsed AML patients, both of which exceeded outcomes with frontline therapy.
Bio-Path 表示，所展示的數據顯示 Prexigebersen 在兩個報告隊列中繼續得到良好的耐受性並展示了有效性結果，包括可評估的新診斷 AML 患者和可評估的難治/復發 AML 患者，兩者的結果均超過了一線治療的結果。
"It was a pleasure to present these compelling data to an audience of European oncologists who treat AML patients and understand the continued great need for new therapeutic options," said Peter Nielsen, CEO of Bio-Path.
“能夠向治療 AML 患者的歐洲腫瘤學家們展示這些令人信服的數據非常愉快，並了解到新療法的極大需求，”Bio-Path 的 CEO Peter Nielsen 表示。
"Given that our study is being conducted in the U.S., this encore presentation is an important step towards educating global oncology leaders on the benefits of prexigebersen and its potential to be another tool in their fight against AML."
“鑑於我們的研究正在美國進行，這次在歐洲大會上的再次演講對於向全球腫瘤治療領袖介紹 Prexigebersen 的益處及其成爲他們戰勝 AML 的又一工具的潛力是非常重要的一步。”
Related News: What's Going On With Longeveron Stock?
相關資訊：龍盛股票出現什麼情況了？
BPTH Stock Prediction 2024:
BPTH 股票 2024 預測：
Equity research can be a valuable source of information for learning about a company's fundamentals. Analysts create financial models based on the fundamentals and expected future earnings of a company to arrive at a price target and recommendation for the stock.
股票研究可以成爲了解公司基本面信息的有價值來源。分析師基於公司未來收益的基本面和預期創建財務模型，以獲得股價目標和股票建議。
Shares of Bio-Path Holdings have an average 1-year price target of $40, representing an expected upside of 1900%.
Bio-Path Holdings 的股票平均一年價格目標爲 40 美元，表示預期上漲 1900%。
Because of differences in assumptions, analysts can arrive at very different price targets and recommendations. No analysts have bearish recommendations on Bio-Path, while 2 analysts have bullish ratings. The street high price target from Roth MKM is $40.
由於假設的差異，分析師可以得出非常不同的價格目標和建議。沒有分析師對 Bio-Path 發表看淡的建議，而有 2 名分析師給出看好的評級。來自 Roth MKM 的最高股價目標是 40 美元。
BPTH Price Action: According to Benzinga Pro, Bio-Path shares are up 13.5% at $2.27 at the time of publication Friday.
BPTH 股價走勢：據 Benzinga Pro 報道，Bio-Path 股票在週五發佈時上漲 13.5%，報價 $2.27。
Image: Shutterstock
圖片：shutterstock
譯文內容由第三人軟體翻譯。